Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies

• DOI: 10.1007/s12325-022-02059-8
• Publication Date: 2022-02-22T12:03:52Z
• Authors: Martin Wabitsch; Sheri Fehnel; Usha G. Mallya; Martina Sluga-O’C...; David Richardson; Mark Price; Peter Kühnen
• Keywords: 2. Zero hunger; Pro-Opiomelanocortin; Hunger; Rare Genetic Diseases of Obesity; Pro-Opiomelanocortin [MeSH] ; Pro-Opiomelanocortin ; Disease Burden ; Humans [MeSH] ; Patient Outcome Assessment [MeSH] ; Hyperphagia/drug therapy [MeSH] ; Melanocortin Receptor ; Medical and Health Sciences ; Hunger [MeSH] ; Quality of Life [MeSH] ; Hyperphagia ; Original Research ; Leptin Receptor ; Rare Genetic Diseases of Obesity ; alpha-MSH/analogs; Melanocortin Receptor; 610; Leptin Receptor; Hyperphagia; Disease Burden; 3. Good health; Patient Outcome Assessment; 03 medical and health sciences; 0302 clinical medicine; alpha-MSH; Quality of Life; Humans; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit; Original Research

Introduction In patients with pro-opiomelanocortin (POMC) or leptin receptor (LEPR) deficiency, managing obesity and hyperphagia can be burdensome for patients and caretakers. The impacts on health-related quality of life are under-recognized and are not well characterized. Methods We conducted in-depth qualitative interviews in patients with POMC (n = 3) and LEPR (n = 2) deficiencies participating in an ongoing open-label extension of phase 3 clinical trials with the melanocortin receptor 4 agonist setmelanotide to describe the patient experience of hyperphagia and characterize changes following treatment with setmelanotide. Results Prior to setmelanotide treatment, all five patients described abnormal sensations of hunger with none indicating feeling satiated after meals and also reported that the burden of hyperphagia impacted their families, emotions, and work and/or school functioning. Following setmelanotide treatment, all five patients reported consistent reductions in hunger and weight, decreased eating, and feeling satiated after meals in addition to substantial improvements in each area of functioning they had previously reported. All five patients indicated they were very satisfied with the impact of setmelanotide on their quality of life and would be upset if treatment was discontinued. Conclusions In patients with POMC or LEPR deficiency, hyperphagia and the inability to feel satiety negatively impacted quality of life. By reducing hunger and improving satiety, setmelanotide facilitated important changes in the lives of these patients. This qualitative research study suggests that the impact of setmelanotide goes beyond favorable clinical changes (e.g., weight and hunger) to also include quality of life improvements that are highly meaningful to patients.